Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Algeta
Algeta
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Pharmaceutical
Thomas Ramdahl appointed as Managing Director of Algeta
Bayer has completed the acquisition of the Norwegian developer of cancer drugs
Research & Development
Algeta appoints Chief Scientific Officer
Dr Andreas Menrad takes responsibility for the Norwegian company\'s research strategy
Manufacturing
Algeta opens commercial production facility for Xofigo in Norway
The plant for the manufacture of the cancer treatment is based at the Institute for Energy Technology (IFE) in Norway
Manufacturing
Cobra Biologics and Algeta sign monoclonal antibody manufacturing agreement
Cobra to provide cell line development, cell banking, process development, scale-up, GMP production and stability studies
Norwegian cancer therapeutics developer appoints president
Jeffrey Albers takes up the role at Algeta US
Regulatory
Anticancer agent – radium-223 chloride
Radiotherapy commonly involves directing beams of radioactive particles at the tumour, or a radioactive source being placed within the body
Research & Development
Algeta wins grant to develop alpha-pharmaceuticals based on Thorium-227
Norwegian firm to create pipeline of cancer-destroying drugs
Subscribe now